Henlius (02696.HK) announced that the application for phase 1b/2 clinical trial of injection HLX43 (targeting PD-L1 antibody - novel DNA topoisomerase I inhibitor conjugate drug) as monotherapy or combination therapy for advanced/metastatic solid tumors has been approved by the National Medical Products Administration. The company plans to conduct relevant clinical trials in China upon meeting certain conditions.

HLX43 is a PD-L1 targeting antibody conjugate drug developed by the company using a novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker introduced under license from Yilang Biomedical in Suzhou and the company's independently developed PD-L1 targeting antibody.